May 23, 2017
“The clinical course of newly diagnosed, advanced NSCLC can be rapid, with prognoses typically measured in months. Early intervention with appropriately targeted therapies can increase the overall chance of survival, and therefore speed is critical when obtaining biomarker information that might influence the design and initiation of a therapeutic strategy. However, the results from tumor ... Read more
March 14, 2017 China Television (CGTV) recently produced a story about Biodesix’s recent agreement with Bioyong to bring a version of the VeriStrat test to China. The story includes an explanation of how VeriStrat works, from Dr. Gary Pestano.
December 28, 2016 “VeriStrat appears to be a robust assay and should be used for EGFR wild-type patients with squamous cell lung cancer,” says study author Glenwood D. Goss, MD, professor of medicine and an oncologist in the division of medical oncology at the University of Ottawa. Biodesix presented data relating to immunotherapy selection, afatinib efficacy.
January 28, 2016 Adoption of GeneStrat by oncologists is helping to drive greater adoption of VeriStrat, Biodesix’s proteomic test for assessing a patient’s prognosis and predicting response to drug treatment.